Kathy Manchulenko

USPTO Granted Patents = 8 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 11.2

ph-index = 5

Forward Citations = 112(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2007-2024

Loading Chart...

8 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11976103 - Interleukin-2 muteins for the expansion of T-regulatory cells (2024-05-07),

2. 11919953 - TIGIT and CD112R blockade (2024-03-05),

3. 10851144 - Interleukin-2 muteins for the expansion of T-regulatory cells (2020-12-01),

4. 8101178 - Antibodies directed to tumor necrosis factor and uses thereof (2012-01-24),

5. 7994302 - Fully human monoclonal antibodies to IL-13 (2011-08-09),

6. 7585500 - Fully human monoclonal antibodies to IL-13 (2009-09-08),

7. 7572444 - Binding proteins specific for human matriptase (2009-08-11),

8. 7285269 - Antibodies directed to tumor necrosis factor (2007-10-23),

Title: The Innovative Contributions of Kathy Manchulenko

Introduction: Kathy Manchulenko is a distinguished inventor based in Port Coquitlam, Canada, known for her cutting-edge contributions to biopharmaceuticals. With a remarkable portfolio of eight patents, she has made significant strides in the field of immunotherapy, particularly in the enhancement of T-regulatory cells.

Latest Patents: Among her latest innovations are advancements in interleukin-2 muteins designed to expand T-regulatory cells. These patents include IL-2 muteins, IL-2 mutein Fc-fusion molecules, and complexes involving anti-IL-2 antibodies that are suitable for large-scale production. Furthermore, her patents encompass TIGIT and CD112R binding proteins, along with related pharmaceutical compositions and methods that hold the potential for treating various medical conditions through innovative immune modulation.

Career Highlights: Kathy's career in the biopharmaceutical industry has been marked by influential roles at prominent companies such as Amgen Inc. and Amgen Fremont Inc. Her work has not only advanced understanding in her field but has also facilitated significant developments in therapeutic strategies against complex diseases.

Collaborations: Throughout her professional journey, Kathy has collaborated with esteemed colleagues including Ian Nevin Foltz and Jaspal Singh Kang. These collaborations reflect a collective effort to push the boundaries of medical science and improve treatment options for patients in need.

Conclusion: Kathy Manchulenko stands out as an inspiring inventor whose work continues to influence the landscape of immunotherapy. With her extensive patent portfolio and valuable collaborations, she is paving the way for future innovations that can enhance treatment efficacy and patient outcomes.

This text is generated by artificial intelligence and may not be accurate.